Laboratory Management Policies

Medical Mutual is working with Avalon Healthcare Solutions to implement a new Laboratory Management Program, which will go into effect on July 1, 2024.

The Laboratory Management Program includes new and revised laboratory policies and guidelines that will impact certain laboratory services, tests and procedures. These policies are based on the latest science for clinically accepted, peer-reviewed guidelines for lab services, and are available in the links below.

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

A

Allergen Testing - G2031

B

B-Hemolytic Streptococcus Testing - G2159

Biomarker Testing for Autoimmune Rheumatic Disease - G2022

Biomarkers for Myocardial Infarction and Chronic Heart Failure - G2150

Biochemical Markers Of Alzheimer Disease and Dementia - G2048

Bone Turnover Markers Testing - G2051

C

Cardiovascular Disease Risk Assessment - G2050

Celiac Disease Testing - G2043

Cervical Cancer Screening - G2002

Colorectal Cancer - G2181

Coronavirus Testing in the Outpatient Setting - G2174

D

Diabetes Mellitus Testing - G2006

Diagnosis of Idiopathic Environmental Intolerance - G2056

Diagnosis of Vaginitis - M2057

Diagnostic Testing Of Common Sexually Transmitted Infections - G2157

Diagnostic Testing of Influenza - G2119

Diagnostic Testing of Iron Homeostasis & Metabolism - G2011

E

Epithelial Cell Cytology In Breast Cancer Risk Assessment - G2059

Evaluation of Dry Eyes - G2138

F

Fecal Analysis in The Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing - G2060

Fecal Calprotectin Testing - G2061

Flow Cytometry - F2019

Folate Testing - G2154

G

Gamma-glutamyl Transferase - G2173

General Inflammation Testing - G2155

H

Helicobacter Pylori Testing - G2044

Hepatitis Testing - G2036

Human Immunodeficiency Virus (HIV) - M2116

I

Identification Of Microorganisms Using Nucleic Acid Probes - M2097

Immune Cell Function Assay - G2098

Immunohistochemistry - P2018

Immunopharmacologic Monitoring of Therapeutic Serum Antibodies - G2105

In Vitro Chemoresistance And Chemosensitivity Assays - G2100

Intracellular Micronutrient Analysis - G2099

L

Laboratory Testing for the Diagnosis of Inflammatory Bowel Disease - G2121

Lyme Disease Testing - G2143

M

Measurement Of Thromboxane Metabolites For ASA Resistance - G2107

Metabolite Markers For Thiopurines Testing - G2115

N

Nerve Fiber Density - M2112

O

Onychomycosis Testing - M2172

Oral Cancer Screening and Testing - G2113

P

Pancreatic Enzyme Testing for Acute Pancreatitis - G2153

Parathyroid Hormone, Phosphorus, Calcium, and Magnesium Testing - G2164

Pathogen Panel Testing - G2149

Pediatric Preventive Screening - G2042

Prenatal Screening (Nongenetic) - G2035

Prescription Medication and Illicit Drug Testing in the Outpatient Setting - T2015

Prostate Biopsy Specimen Analysis - G2007

Prostate Specific Antigen (PSA) Testing - G2008

S

Salivary Hormone Testing - G2120

Serum Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases - G2123

Serum Testing for Evidence of Mild Traumatic Brain Injury - G2151

Serum Testing for Hepatic Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease - G2110

Serum Tumor Markers for Malignancies - G2124.

T

Testing For Alpha-1 Antitrypsin Deficiency - M2068

Testing for Diagnosis of Active or Latent Tuberculosis - G2063

Testing for Vector-Borne Infections - G2158

Testosterone - G2013

Thyroid Disease Testing - G2045

U

Urinary Tumor Markers For Bladder Cancer - G2125

Urine Culture Testing for Bacteria - G2156

V

Venous and Arterial Thrombosis Risk Testing - M2041

Vitamin B12 and Methylmalonic Acid Testing - G2014

Vitamin D Testing - G2005

Medical Mutual Laboratory Management Program Policies Disclaimer

Medical Mutual has collaborated with Avalon Healthcare Solutions (Avalon) on a Laboratory Management Program. The Laboratory Management Program includes certain Laboratory Services Policies (the “Laboratory Policies”) that offer guidance for payment determinations for a laboratory service or guidance for the way a laboratory service should be billed to Medical Mutual. The provider is responsible for submission of accurate claims.

The Laboratory Policies have been developed to assist in administering proper payment under benefit plans. Benefit plans vary in coverage and some plans may not provide coverage for some services discussed in these Laboratory Policies. Benefit determinations, coverage decisions, and payment determinations are subject to all terms and conditions of the applicable benefit plan, including definitions, specifically stated benefits, exclusions and benefit limitations, applicable state or federal laws, and other Laboratory Policies, Medical Mutual Corporate Reimbursement Policies, and Medical Mutual Corporate Medical Policies. Laboratory Policies are not intended to address every issue related to reimbursement of health care services, and Medical Mutual may use reasonable discretion in interpreting and applying Laboratory Policies to particular cases.

Laboratory Policies are considered guidelines and are not intended to infer or eliminate benefits or coverage for a specific member. Payment determinations are based on the specific facts regarding the service provided and how that service is billed.

Laboratory Policies do not constitute medical advice or medical care. The healthcare provider treating the member is solely responsible for the medical advice and treatment rendered to the member. Only the treating provider can deliver medical care and be responsible for the quality or appropriateness of the medical care and the skill with which it is provided.

Medical Mutual coverage decisions are benefit decisions only. Medical Mutual is not responsible for, does not provide and does not represent itself as a provider of medical care. If a service or supply is not eligible for benefits as determined by Medical Mutual, a member and the treating provider may proceed with that service or supply; however, benefits will not be available under the member’s plan.

Laboratory Policies are regularly reviewed, updated, withdrawn or added and therefore, subject to change. Payment determinations are made in the context of Laboratory Policies and other Medical Mutual policies, including Corporate Reimbursement Policies and Corporate Medical Policies, existing at the time the determination is made and are not subject to later revision as a result of a change in Laboratory Policy.